<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02574585</url>
  </required_header>
  <id_info>
    <org_study_id>SCI-005</org_study_id>
    <nct_id>NCT02574585</nct_id>
  </id_info>
  <brief_title>Autologous Mesenchymal Stem Cells Transplantation in Thoracolumbar Chronic and Complete Spinal Cord Injury Spinal Cord Injury</brief_title>
  <official_title>Randomized Clinical Trial for the Evaluation of Autologous Mesenchymal Stem Cells Transplantation in Thoracolumbar Chronic and Complete Spinal Cord Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Sao Rafael</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Sao Rafael</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to analyze the safety and efficacy of autologous bone marrow&#xD;
      mesenchymal stem cell transplantation in patients with thoracolumbar chronic and complete&#xD;
      spinal cord injury.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, non-placebo controlled, prospective, phase II clinical trial. The study&#xD;
      population will consist of 40 patients who had spinal cord injury for at least 12 months,&#xD;
      with thoracolumbar chronic and complete spinal cord injury, ASIA grade A.&#xD;
&#xD;
      A practitioner, a surgeon and a nurse will review the medical records of the patients to&#xD;
      determine the presence / absence of inclusion / exclusion criteria. If the patient is a&#xD;
      potential candidate for the study, an interview will be scheduled to review and confirm&#xD;
      his/her eligibility. Patients will undergo a series of clinical and neurological assessments&#xD;
      and will also be submitted to the following procedures:&#xD;
&#xD;
        -  Cell blood count;&#xD;
&#xD;
        -  Biochemical analysis (measurement of electrolytes - sodium, potassium, magnesium);&#xD;
&#xD;
        -  Renal function tests (urea and creatinine);&#xD;
&#xD;
        -  Liver function tests;&#xD;
&#xD;
        -  Coagulation profile;&#xD;
&#xD;
        -  Metabolic profile (glucose, total cholesterol and fractions);&#xD;
&#xD;
        -  Urine summary and culture;&#xD;
&#xD;
        -  Serology required for blood transfusion and marrow transplant in Brazil;&#xD;
&#xD;
        -  Electrocardiogram;&#xD;
&#xD;
        -  Chest X-Ray;&#xD;
&#xD;
        -  Bone densitometry;&#xD;
&#xD;
        -  Urodynamic studies;&#xD;
&#xD;
        -  Somatosensory evoked potential;&#xD;
&#xD;
        -  Computed tomography of thoracic and lumbar spine;&#xD;
&#xD;
        -  Magnetic resonance imaging of the thoracic and lumbar spine.&#xD;
&#xD;
      Also as part of the preoperative evaluation, the patients will respond to questions from the&#xD;
      SF (Short Form) -36 questionnaire (for assessment of quality of life) and the questionnaires&#xD;
      for the assessment of neuropathic pain. Clinical follow-up will be kept for patients who&#xD;
      suspend their participation in the study for any adverse event and / or laboratory&#xD;
      abnormality, or for the patient's own desire, following insurance protocols. In addition to&#xD;
      the clinical and surgical follow-up, specific medical care will be offered to patients who&#xD;
      experience adverse events, until stabilization of the patient, even if the target date for&#xD;
      completion of the study has been exceeded. The candidates included in the study will be asked&#xD;
      to voluntarily participate and give their informed written consent.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2019</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by magnetic resonance imaging spinal cord injury</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional improvement in ASIA (American Spinal Injury Association) grade</measure>
    <time_frame>12 months</time_frame>
    <description>The investigators will evaluate the conversion rate from ASIA A to B or C in 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional improvement regarding the AIS (ASIA Impairment Scale) scores (light touch, pin prik and motor force)</measure>
    <time_frame>12 months</time_frame>
    <description>AIS (ASIA Improvement Scale) degree on the ASIA score will be assessed in order to evaluate sensitivity and motor force in 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvements in sensorial mapping and neuropathic pain</measure>
    <time_frame>12 months</time_frame>
    <description>The patients will be submitted to specific questionnaires and clinical examinations in order to evaluate improvements in sensorial mapping and neuropathic pain.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Spinal Cord Injury</condition>
  <arm_group>
    <arm_group_label>Treated group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twenty subjects will be randomly assigned to receive two percutaneous injections of mesenchymal stem cells, with a 3-month interval between the injections.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Twenty subjects will be randomly assigned to be clinically followed, without any specific intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous mesenchymal cells transplantation</intervention_name>
    <description>Two percutaneous injections of mesenchymal stem cells, with a 3-month interval between the injections.</description>
    <arm_group_label>Treated group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Blunt spinal cord injury at thoracolumbar level, between T1 and L2, or penetrating&#xD;
             spinal cord injury, at the same level, provided that the mechanism of injury had been&#xD;
             spinal shock, ischemia or hematoma, with at least 12 months of injury;&#xD;
&#xD;
          -  ASIA grade A;&#xD;
&#xD;
          -  Signing of the written consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Spinal cord injuries by sharp objects, firearms, and not traumatic or congenital&#xD;
             causes, even if at different levels of the spinal cord;&#xD;
&#xD;
          -  Concomitant brain injuries;&#xD;
&#xD;
          -  Diabetes mellitus type 1 or 2 as defined by fasting glucose above 126 mg / use of&#xD;
             medication and medical history;&#xD;
&#xD;
          -  Infectious processes in acute and / or chronic course, confirmed by additional tests&#xD;
             and / or medical history;&#xD;
&#xD;
          -  Immunodeficiency, autoimmune diseases and neoplastic processes, confirmed by&#xD;
             additional tests and / or medical history;&#xD;
&#xD;
          -  Terminal, neurodegenerative, primary hematologic and musculoskeletal diseases&#xD;
             confirmed by additional tests and / or past medical history;&#xD;
&#xD;
          -  Osteopathies reflecting increased risk for bone marrow puncture;&#xD;
&#xD;
          -  Coagulopathies;&#xD;
&#xD;
          -  Severe organ failure (heart, kidney or liver), confirmed by additional tests or&#xD;
             medical history;&#xD;
&#xD;
          -  Pregnancy or lactation;&#xD;
&#xD;
          -  Clinical complications that hinder or contraindicate the surgical procedure;&#xD;
&#xD;
          -  Use of metallic implants near vascular structures (such as cardiac pacemaker), or&#xD;
             other contraindication to magnetic resonance imaging;&#xD;
&#xD;
          -  Psychiatric disorders, psychosocial and cognitive impairment confirmed by medical&#xD;
             evaluation;&#xD;
&#xD;
          -  Abusive use of alcohol and / or illegal substances use;&#xD;
&#xD;
          -  Participation in other clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ricardo Ribeiro-dos-Santos, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital SÃ£o Rafael</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Milena BP Soares, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital SÃ£o Rafael</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bruno SF Souza, MD, Msc</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital SÃ£o Rafael</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ticiana F Larocca, MD, Msc</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital SÃ£o Rafael</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rodrigo L Alves, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital SÃ£o Rafael</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carolina T Macedo, MD, MSc</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital SÃ£o Rafael</affiliation>
  </overall_official>
  <overall_official>
    <last_name>AndrÃ© C Matos, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital SÃ£o Rafael</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cristiane F Villarreal, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital SÃ£o Rafael</affiliation>
  </overall_official>
  <overall_official>
    <last_name>AntÃ´nio OlÃ­mpio S Moura, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital SÃ£o Rafael</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eduardo BrazÃ£o, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital SÃ£o Rafael</affiliation>
  </overall_official>
  <overall_official>
    <last_name>KÃ¡tia N Silva, MSc</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital SÃ£o Rafael</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniela N Silva, MSc</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital SÃ£o Rafael</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Clarissa LM de Souza, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital SÃ£o Rafael</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ricardo Ribeiro-dos-Santos, PhD</last_name>
    <phone>+557132816455</phone>
    <email>ricardoribeiro@cbtc-hsr.org</email>
  </overall_contact>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>April 10, 2015</study_first_submitted>
  <study_first_submitted_qc>October 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2015</study_first_posted>
  <last_update_submitted>November 27, 2017</last_update_submitted>
  <last_update_submitted_qc>November 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Sao Rafael</investigator_affiliation>
    <investigator_full_name>Ricardo Ribeiro dos Santos</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>Spinal cord injury</keyword>
  <keyword>Paraplegia</keyword>
  <keyword>Stem cells</keyword>
  <keyword>Mesenchymal cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Cord Injuries</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

